Efter aflæggelse af Q2 regnskabet afholdte Demants ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Demant indleder præsentationen sådan:
- -18% growth for the Group in LCY due to severe impact of coronavirus, consisting of -27 pp organic
growth and 9 pp acquisitive growth driven by the consolidation of EPOS. - Group gross profit margin decreased by 7.6 pp to 70.0% adjusted for EPOS one-offs. Decrease primarily
due to significant revenue drop but also to a dilution from the consolidation of EPOS of slightly more than
2 pp and to increasing sales of rechargeable hearing aids as well as higher freight costs. - 14% organic decrease in Group capacity costs (29%* organic decrease in Q2). Reductions driven by
furloughs and savings in distribution and administration functions, particularly in hearing aid retail. R&D
commitment deliberately maintained. Total headcount reduced by 600 (excl. EPOS) compared to the
beginning of the year, mainly in operations. - Operating profit (EBIT) of DKK -193 million before net positive EPOS one-offs, including a provision for
additional bad debt of DKK 150 million. Reported EBIT of DKK 114 million. - Cash flow from operating activities (CFFO) before EPOS one-offs decreased by 27% to DKK 766 million.
CFFO was less severely impacted than profits, primarily due to working capital improvements.
